



Truenat[®] for Sexually Transmitted Infections

Chip-based Real-Time PCR Test for
HIV-1/HIV-2, HPV-HR Plus, HSV-1/2,
CT/NG & Trich

Every day
1 million+
 people acquire
 an STI¹

In 2020 alone, an estimated
374 million
 new cases were caused by
 just four curable STIs

Trichomoniasis
156 million

Chlamydia
129 million

Gonorrhoea
82 million

Syphilis
7.1 million

Most remain undiagnosed, yet the consequences are real:



Infertility



Neonatal infections



Heightened HIV
 susceptibility



Pelvic inflammatory
 disease

With rising STI burden and growing resistance to syndromic approaches, accurate, decentralised diagnosis is more urgent than ever.

Burden

Low - and middle - income countries — especially in sub-Saharan Africa, South and Southeast Asia, and Latin America — carry the highest burden of STIs.²

WHO Diagnostic Recommendations

WHO recommends NAATs as the gold standard for STI diagnosis.

Bridging the Gap with Truenat[®] Assays for Varied STIs

HPV - HR Plus

Protect Against Cervical Cancer and Beyond.

Detects 8 high-risk HPV genotypes (16, 18, 31, 33, 35, 45, 52, 58) linked to cervical and other cancers.

96% of cervical cancer
 cases are associated with
 8 HR - genotypes

Early detection = Early intervention.



HIV - 1/HIV-2

For Detection & Viral Load Monitoring.

Detect early, monitor effectively, and enable timely treatment initiation—even in hard-to-reach areas.

39.9 million people live with HIV globally



HSV - 1/2

Detection of HSV - 1/2 with sensitive NAAT testing.

Clinical symptoms often overlap—lab confirmation is critical. Truenat ensures clarity and control.

Over **520 million** people (13% globally) live with HSV-2



Trichomoniasis (Trich)

Detect and Disrupt Silent Spreaders.

Asymptomatic yet impactful. Truenat detects *Trichomonas vaginalis* quickly to prevent complications like PID and enhance HIV prevention.

156 million new cases in 2020



Chlamydia & Gonorrhoea (CT/NG)

One Assay. Double Detection.

Simultaneous detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—two of the most common STIs globally. If left untreated Chlamydia trachomatis infection can also lead to pelvic inflammatory disease. Estimated annual cases are:

129 million
Chlamydia

82 million
Gonorrhoea

Both are often asymptomatic. Both demand sensitive, NAAT - based diagnosis.



Truenat[®] Makes STI Testing Accessible. Accurate. Actionable.

Reliable molecular diagnostics with lab-grade accuracy – brings advanced STI testing directly to the point of care.



KEY FEATURES



<1 hour turnaround time



Long shelf life

Room temperature stable reagents



User-friendly

Requires minimal human resource training



Lyophilized, ready-to-use PCR reagents



Smart chip

Replete with batch-specific data



Minimal biosafety requirements

Can be used even in resource limited settings

REFERENCE

¹⁻² WHO- Updated recommendations for the treatment of *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Treponema pallidum* (syphilis), and new recommendations on syphilis testing and partner services.



MOLBIO DIAGNOSTICS LIMITED
L-46, Phase II D, Verna Industrial Estate,
Verna, Goa - 403 722, India



+91 832-2783267



sales@molbiodiagnostics.com



www.molbiodiagnostics.com



customersupport@molbiodiagnostics.com